SCHEMBL18094580

SCHEMBL18094580

CC(C)(C)OC(=O)N1CCN(c2cccc(-c3nsc(NC(=O)c4ccc(C(F)(F)F)cc4)n3)n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 4/20 0.46
▸ MAPT P10636 2/20 0.45
▸ TBK1 Q9UHD2 1/20 0.43
▸ KIF18A Q8NI77 1/20 0.43
▸ EIF2AK4 Q9P2K8 1/20 0.41
▸ IDH1 O75874 1/20 0.41
▸ IDH2 P48735 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ GBA1 P04062 1/20 0.40
▸ CKS1B P61024 1/20 0.40
▸ SKP1 P63208 1/20 0.40
▸ SKP2 Q13309 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ GRAMD1A Q96CP6 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ TRPV1 Q8NER1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18094459 0.87 SMN1; SMN2 (0.53) MAPTEIF2AK4SMN1; SMN2
SCHEMBL18094509 0.84 GPR119 (0.47) GPR119MAPTTBK1SMN1; SMN2HTT
SCHEMBL18094536 0.83 MAPT (0.44) MAPTSMN1; SMN2
SCHEMBL18094474 0.79 SMN1; SMN2 (0.49) GPR119MAPTSMN1; SMN2HTTNPSR1
SCHEMBL18094517 0.77 ABL1 (0.49) GPR119
SCHEMBL2304234 0.76 TBK1 (0.56) GPR119TBK1SMN1; SMN2CKS1BSKP1
SCHEMBL18094552 0.75 MAPT (0.52) MAPT
SCHEMBL22936006 0.75 KIF18A (0.57) GPR119KIF18ASMN1; SMN2GBA1CKS1B
SCHEMBL18094524 0.73 ALDH1A1 (0.49) GPR119MAPTIDH1IDH2HTT
SCHEMBL18094481 0.73 USP30 (0.53) GPR119MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170202849-A1 ANTIPARASITIC COMPOUNDS AVISTA PHARMA SOLUTIONS, INC. 2017-07-20 — — US claimed
US-9643963-B2 Antiparasitic compounds AVISTA PHARMA SOLUTIONS, INC. (US) 2017-05-09 — — US claimed
US-20160280700-A1 ANTIPARASITIC COMPOUNDS SNAPDRAGON CHEMISTRY, INC. 2016-09-29 — — US claimed
US-20170202849-A1 ANTIPARASITIC COMPOUNDS AVISTA PHARMA SOLUTIONS, INC. 2017-07-20 — — US disclosed
US-9643963-B2 Antiparasitic compounds AVISTA PHARMA SOLUTIONS, INC. (US) 2017-05-09 — — US disclosed
US-20160280700-A1 ANTIPARASITIC COMPOUNDS SNAPDRAGON CHEMISTRY, INC. 2016-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280700-A1 ANTIPARASITIC COMPOUNDS TPP2, TPP1, SERPINB1 GPR119 4245/4885MAPT 2921/4885TBK1 2219/4885
US-20170202849-A1 ANTIPARASITIC COMPOUNDS TPP2, TPP1, SERPINB1 GPR119 4245/4885MAPT 2921/4885TBK1 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback